Citadel Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Citadel Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-53	Closed	-$1.1K	–	15331
2023 Q4	$1.1K	Sell	53 -27	-34%	-$806	﹤0.01%	13878
2023 Q3	$2.54K	Sell	80 -57	-42%	-$1.9K	﹤0.01%	13701
2023 Q2	$4.59K	Sell	137 -56	-29%	-$2K	﹤0.01%	13584
2023 Q1	$8.06K	Sell	193 -530	-73%	-$24.9K	﹤0.01%	13680
2022 Q4	$24.5K	Sell	723 -1,037	-59%	-$44.1K	﹤0.01%	12960
2022 Q3	$87K	Buy	1,760 +240	+16%	+$13.2K	﹤0.01%	11209
2022 Q2	$60K	Buy	1,520 +1,147	+308%	+$34K	﹤0.01%	11811
2022 Q1	$14K	Buy	+373	New	+$23.3K	﹤0.01%	13332
2021 Q4	–	Sell	-1,280	Closed	-$160K	–	14605
2021 Q3	$160K	Buy	1,280 +313	+32%	+$37.8K	﹤0.01%	12291
2021 Q2	$121K	Sell	967 -2,466	-72%	-$294K	﹤0.01%	12737
2021 Q1	$466K	Sell	3,433 -1,527	-31%	-$190K	﹤0.01%	9824
2020 Q4	$451K	Buy	4,960 +4,330	+687%	+$375K	﹤0.01%	8336
2020 Q3	$47K	Buy	+630	New	+$48.3K	﹤0.01%	9624

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's RNAC Position: Q1 2026 in Review

Citadel Advisors increased its Cartesian Therapeutics (RNAC) stake by 38% in Q1 2026, buying an estimated $216K and bringing the position to 110,128 shares worth $677K. The position accounts for ﹤0.01% of the portfolio, ranked #8565.

Citadel Advisors first reported a position in RNAC in Q4 2018 and has held it in 24 quarters since. The position peaked at $5.76M in Q3 2024. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

Citadel Advisors held 110,128 shares of Cartesian Therapeutics worth $677K as of Q1 2026.
Citadel Advisors bought 30,343 Cartesian Therapeutics shares in Q1 2026, an estimated $216K.
Cartesian Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8565 holding.
Citadel Advisors first reported a position in Cartesian Therapeutics in Q4 2018 and has held it in 24 quarters since.
Citadel Advisors's Cartesian Therapeutics position peaked at $5.76M in Q3 2024.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.